Characteristics of patients with pulmonary MAC with chronic and intermittent co-infection
| Variables | No co-infection (n=110) | Chronic co-infection (n=124) | p Value | Intermittent co-infection (n=41) | p Value |
|---|---|---|---|---|---|
| Age at diagnosis, years | 61.9±11.5 | 61.6±12.3 | 0.91 | 62.8±9.7 | 0.62 |
| Gender (female) | 88 (80.0) | 87 (70.2) | 0.084 | 30 (73.2) | 0.37 |
| Body mass index, kg/m2 | 19.1±2.9 | 19.6±2.8 | 0.37 | 19.8±2.5 | 0.13 |
| Smoking status (never) | 92 (83.6) | 93 (75.0) | 0.11 | 34 (82.9) | 0.92 |
| Underlying disease | |||||
| Bronchiectasis | 92 (83.6) | 108 (87.1) | 0.45 | 34 (82.9) | >0.99 |
| Severe pneumonia (hospitalisation) | 26 (23.6) | 45 (36.3) | 0.036 | 10 (24.4) | 0.92 |
| COPD | 5 (4.6) | 21 (16.9) | 0.0030 | 2 (4.9) | 0.99 |
| Asthma | 7 (6.4) | 14 (11.3) | 0.25 | 3 (7.3) | 0.99 |
| History of tuberculosis | 13 (11.8) | 18 (14.5) | 0.54 | 3 (7.3) | 0.56 |
| History of malignant disease | 17 (15.5) | 30 (24.2) | 0.096 | 10 (24.4) | 0.20 |
| Diabetes mellitus | 9 (8.2) | 11 (8.9) | 0.99 | 6 (14.6) | 0.24 |
| Autoimmune disease | 9 (8.2) | 19 (15.3) | 0.11 | 8 (19.5) | 0.079 |
| Rheumatoid arthritis | 3 (2.7) | 12 (9.7) | 0.034 | 4 (9.8) | 0.087 |
| GORD symptom | 17 (15.5) | 18 (14.5) | 0.86 | 9 (22.5) | 0.33 |
| Use of systemic corticosteroids | 4 (3.6) | 16 (12.9) | 0.017 | 2 (4.9) | 0.66 |
| Use of immunosuppressant agent | 5 (4.6) | 13 (10.5) | 0.14 | 6 (14.6) | 0.07 |
| Use of inhaled corticosteroids | 4 (3.6) | 13 (10.5) | 0.074 | 2 (4.9) | 0.73 |
| Infected MAC strain (Mycobacterium intracellulare) | 16 (14.6) | 36 (29.3) | 0.0053 | 13 (33.3) | 0.011 |
| Duration of MAC disease, years | 6.3±5.0 | 8.5±8.6 | 0.15 | 5.7±5.3 | 0.39 |
| History of MAC treatment | 76 (69.1) | 81 (65.3) | 0.54 | 27 (65.9) | 0.70 |
| MAC sputum culture conversion | 74 (67.3) | 87 (70.2) | 0.63 | 31 (75.6) | 0.32 |
Data show either the number (%) of patients or the mean±SD.
COPD, chronic obstructive pulmonary disease; GORD, gastro-oesophageal reflux disease; MAC, M. avium complex.